Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Ablynx Extends Agreement with Wyeth for One Year

  • Ablynx extended its TNF-alpha partnership with Wyeth Pharmaceuticals for another year. The alliance is based on Ablynx’ Nanobody® technology.

    Under the terms of the original agreement, the companies will collaborate to advance novel biologics through clinical development. Wyeth has the exclusive rights to the development and commercialization of the anti-TNF-alpha Nanobodies developed under this agreement.

    Ablynx has already received an initial payment for research. Potential fees could total up to $212.5 million for development. Ablynx will also get royalties on product sales.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »